Evidence map›Paper›PMID 28434490›Full record

ArticleThe lancet. Diabetes & endocrinology2017

Semaglutide, lipid-lowering drugs, and NAFLD.

Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.International journal of molecular sciences · 2020
    Review
  6. The Discovery and Development of Liraglutide and Semaglutide.Frontiers in endocrinology · 2019 · on this map
    Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Niki KatsikiSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
Vasilios G AthyrosSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
Asterios KaragiannisSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
Dimitri P MikhailidisDepartment of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London, London NW3 2QG, UK. Electronic address: mikhailidis@aol.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Glucagon-Like PeptidesNon-alcoholic Fatty Liver DiseaseHumansHypoglycemic AgentsLipidsSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsLipidsSemaglutide

Identifiers

PMID28434490

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.